GALC and lung carcinoma: In keeping with this hypothesis, immunohistochemical data have shown that high levels of GALC immunoreactivity are associated with poor prognosis in colorectal cancer patients [41] and that higher GALC expression levels in circulating lung cancer cells correlate with a poor response to therapy, representing a possible predictor biomarker in these patients [42].